News
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015
-
- 31 May 2022 Alligator Bioscience to Present Additional data of ATOR-1017 First-in-Human Study via poster presentation at ASCO Annual Meeting 2022
- 09 May 2022 Alligator Bioscience expands its Board of Directors with the appointment of Staffan Encrantz and Denise Goode
- 05 May 2022 Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2022 R
- 27 Apr 2022 Alligator Bioscience AB: Interim report January–March 2022 R
- 22 Apr 2022 Invitation to the Presentation of Alligator Bioscience´s Interim Report January - March 2022 on April 27, 2022 R
- 05 Apr 2022 Notice of annual general meeting in Alligator Bioscience AB R
- 01 Apr 2022 Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences
- 31 Mar 2022 Change in number of shares and votes in Alligator Bioscience AB R
- 23 Mar 2022 Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg
- 22 Mar 2022 Issue and repurchase of series C shares for performance-based share saving program R
- 22 Mar 2022 Alligator Bioscience publishes Annual Report for 2021 R
- 11 Mar 2022 The Nomination Committee’s proposal regarding the Board of Directors ahead of the Annual General Meeting 2022 in Alligator Bioscience AB R
- 11 Feb 2022 Alligator Bioscience AB: Year End report January–December 2021 R
- 04 Feb 2022 Invitation to the Presentation of Alligator Bioscience´s Year-End Report January - December 2021 on February 11, 2022 R
- 01 Feb 2022 Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical Officer
- 20 Jan 2022 Nomination Committee Appointed in Respect of AGM 2022 in Alligator Bioscience AB R
- 19 Jan 2022 Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty
- 18 Jan 2022 Alligator Bioscience Announces OPTIMIZE-1 Trial Update: Cohort Fully Dosed with No Adverse Effects Reported
- 07 Jan 2022 Alligator Bioscience to Participate in Upcoming Investor Conferences
-
- 30 Dec 2021 Change in number of shares and votes in Alligator Bioscience AB R
- 16 Dec 2021 Last day of trading in paid subscription shares (Sw. BTA) in Alligator R
- 16 Dec 2021 Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability Data
- 15 Dec 2021 Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal Nature Communication
- 02 Dec 2021 Alligator carries out a directed issue of shares to guarantors in connection with the completed rights issue R
- 01 Dec 2021 Alligator announces final outcome of rights issue R
- 29 Nov 2021 Alligator announces preliminary outcome of rights issue R
- 12 Nov 2021 Alligator Announces Poster Presentation on ATOR-1017 at SITC Virtual Annual Meeting 2021
- 12 Nov 2021 Alligator Announces Poster Presentation on Neo-X-Prime™ presenting data on the lead compound targeting CD40 and CEA at SITC Virtual Annual Meeting 2021
- 12 Nov 2021 Alligator Announces Poster Presentation on OPTIMIZE-1 at SITC Virtual Annual Meeting 2021
- 12 Nov 2021 Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
- 12 Nov 2021 The subscription period in Alligator Bioscience's rights issue begins today R
- 10 Nov 2021 Alligator Bioscience to Participate in Upcoming Investor Conferences
- 09 Nov 2021 Alligator Bioscience publishes prospectus in connection with forthcoming rights issue R
- 08 Nov 2021 Alligator Bioscience Announces Commencement of Investigator Initiated Phase I Clinical Trial at Erasmus University Rotterdam R
- 08 Nov 2021 Bulletin from the extraordinary general meeting in Alligator Bioscience AB R
- 03 Nov 2021 Nomination Committee appointed in respect of AGM 2022 in Alligator Bioscience AB R
- 22 Oct 2021 Alligator enters into agreements on subscription commitments with board members and senior executives R
- 21 Oct 2021 Alligator Bioscience AB: Correction regarding MAR marking
- 21 Oct 2021 Alligator Bioscience AB: Interim report January–September 2021 R
- 21 Oct 2021 Alligator Announces First Patient Dosed in Phase II Clinical Trial with Shanghai Henlius Biotech, Inc. & AbClon, Inc. R
- 15 Oct 2021 Invitation to the Presentation of Alligator Bioscience´s Interim Report January - September 2021 on October 21, 2021 R
- 07 Oct 2021 Notice of extraordinary general meeting in Alligator Bioscience AB R
- 07 Oct 2021 Alligator carries out a 100 percent secured rights issue of approximately SEK 257 million R
- 30 Sep 2021 Alligator Bioscience Announces First Patient Dosed in OPTIMIZE-1 Phase II Clinical Trial Evaluating Mitazalimab in Combination with mFOLFIRINOX for the Treatment of Pancreatic Cancer R
- 22 Sep 2021 Alligator to Participate in Upcoming Investor Conferences
- 02 Sep 2021 Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline R
- 02 Sep 2021 Positive Results from the Scandion Oncology and Alligator Bioscience Collaboration Further Supports Efficacy of Mitazalimab in Combination Therapy
- 18 Aug 2021 Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation R
- 16 Aug 2021 Alligator Bioscience Announces New Senior Director of Communications & Investor Relations
- 13 Jul 2021 Alligator Bioscience AB: Interim report January–June 2021 R
- 30 Jun 2021 Alligator Bioscience AB and Scandion Oncology A/S present promising preclinical data
- 07 Jun 2021 Article on CD40 agonistic antibodies published in Expert Opinion on Biological Therapy
- 04 Jun 2021 Alligator Bioscience presents positive Phase I data at ASCO for its 4-1BB agonist drug candidate ATOR-1017 R
- 01 Jun 2021 Bulletin from the annual general meeting in Alligator Bioscience AB on June 1, 2021 R
- 05 May 2021 Alligator’s mitazalimab shown to enhance cancer vaccine
- 04 May 2021 Alligator Bioscience and BioArctic enter into research agreement in the neurodegenerative field
- 30 Apr 2021 Board member in Alligator Bioscience resigns at his own request R
- 27 Apr 2021 Alligator Bioscience AB: Interim report January–March 2021 R
- 26 Apr 2021 Notice of annual general meeting in Alligator Bioscience AB R
- 22 Apr 2021 The Nomination Committee’s proposal regarding the board of directors ahead of the annual general meeting 2021 in Alligator Bioscience AB R
- 15 Apr 2021 Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy
- 03 Apr 2021 Alligator Bioscience postpones the Annual General Meeting to June 1, 2021 R
- 18 Mar 2021 Alligator Bioscience appoints Søren Bregenholt as new CEO R
- 18 Mar 2021 Alligator Bioscience publishes Annual Report for 2020 R
- 11 Mar 2021 Mitazalimab synergizes with chemotherapy - Alligator Bioscience presents new preclinical data at AACR
- 26 Feb 2021 Change in number of shares and votes in Alligator Bioscience AB R
- 26 Feb 2021 Alligator Bioscience AB: Year-end Report January-December 2020 R
- 23 Feb 2021 Alligator Bioscience AB: Last day of trading in paid subscription shares (Sw. BTA) R
- 27 Jan 2021 Alligator Bioscience’s rights issue oversubscribed R
- 21 Jan 2021 Larger shareholder and board member transfer subscription rights free of charge to qualified investors R
- 15 Jan 2021 Alligator Bioscience appoints Chief Scientific Officer R
- 11 Jan 2021 The subscription period in Alligator Bioscience’s rights issue commences today R
-
- 30 Dec 2020 Alligator Bioscience publishes prospectus in connection with forthcoming rights issue R
- 29 Dec 2020 Alligator Bioscience recruits new Chief Medical Officer R
- 28 Dec 2020 Alligator Bioscience submits CTA for the mitazalimab Phase II study OPTIMIZE-1 R
- 15 Dec 2020 Alligator carries out a fully guaranteed rights issue of approximately SEK 86m R
- 10 Dec 2020 Alligator Bioscience launches ALLIGATOR-FAB™ – a novel human antibody library R
- 04 Dec 2020 Approved IND for Alligator Bioscience’s CD40-targeting antibody mitazalimab R
- 20 Nov 2020 Nomination Committee appointed in respect of AGM 2021 in Alligator Bioscience AB R
- 16 Nov 2020 Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development R
- 09 Nov 2020 Alligator Bioscience presents at the SITC 35th Annual Meeting R
- 05 Nov 2020 Alligator Bioscience presents the CD40 antibody mitazalimab at the World Immunotherapy Congress 2020 R
- 27 Oct 2020 Predicted therapeutic range dose levels reached in ATOR-1017 Phase I R
- 22 Oct 2020 Alligator Bioscience AB (publ): Interim report January-September 2020 R
- 22 Oct 2020 Alligator Bioscience focuses on ATOR-1017 and mitazalimab R
- 28 Sep 2020 Alligator Bioscience appoints Gayle Mills as Chief Business Officer R
- 24 Sep 2020 Alligator Bioscience launches a new immuno-oncology concept R
- 16 Sep 2020 Alligator Bioscience receives patent approval for the drug candidate ATOR-1015 R
- 09 Sep 2020 Alligator Bioscience presents an update regarding the Phase I study with the drug candidate ATOR-1015 R
- 04 Sep 2020 Alligator Bioscience presents positive biomarker data demonstrating proof of mechanism in mitazalimab clinical Phase I study R
- 27 Aug 2020 Alligator Bioscience: Encouraging interim safety data in ATOR-1017 clinical Phase I study R
- 25 Aug 2020 Alligator Bioscience presents the clinical project portfolio at Virtual R&D Day August 27, 2020 R
- 13 Jul 2020 Alligator Bioscience AB (publ) Interim report January-June 2020 R
- 23 Jun 2020 Alligator Bioscience receives first patent approval for ATOR-1017 R
- 15 Jun 2020 Alligator Bioscience appoints new CFO R
- 10 Jun 2020 Aptevo Therapeutics and Alligator Bioscience present new preclinical data for ALG.APV-527 at the PEGS Virtual Interactive Global Summit R
- 04 Jun 2020 Alligator Bioscience and Scandion Oncology sign preclinical agreement to explore combination therapies for chemotherapy and immuno-oncology R
- 01 Jun 2020 Alligator Bioscience’s collaboration with Biotheus Inc. proceeds and second payment is received R
- 29 May 2020 Alligator Bioscience presents novel supportive Phase I data at ASCO for its CTLA-4 x OX40 bispecific drug candidate ATOR-1015 R
- 05 May 2020 Bulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2020 R
- 27 Apr 2020 Alligator Bioscience presents promising interim Phase I data for its bispecific drug candidate ATOR-1015 at AACR R
- 23 Apr 2020 Alligator Bioscience AB (publ) Interim report January-March 2020 R
- 20 Apr 2020 Alligator Bioscience's Board of Directors reduces its fees and offers possibility for postal voting in front of the Annual General Meeting R
- 07 Apr 2020 Alligator Bioscience increases focus on clinical development R
- 01 Apr 2020 Alligator Bioscience informs about temporary halt of recruitment of new patients due to the covid-19 pandemic R
- 31 Mar 2020 Notice of annual general meeting in Alligator Bioscience AB (publ) R
- 05 Mar 2020 Alligator Bioscience appoints Andreas Johannesson as interim Chief Financial Officer R
- 02 Mar 2020 Alligator Bioscience’s Annual Report 2019 published R
- 12 Feb 2020 Alligator Bioscience AB Year-end Report January-December 2019 R
-
- 17 Dec 2019 Alligator Bioscience: First patient dosed with ATOR-1017 developed for metastasized cancer R
- 11 Dec 2019 CFO Per-Olof Schrewelius leaves Alligator Bioscience R
- 29 Nov 2019 Alligator Bioscience AB appoints Chief Operating Officer R
- 13 Nov 2019 Nomination Committee appointed in respect of AGM 2020 in Alligator Bioscience AB R
- 08 Nov 2019 Aptevo Therapeutics and Alligator Bioscience present new preclinical data for ALG.APV-527 at the Society for Immunotherapy of Cancer 2019 Annual Meeting R
- 06 Nov 2019 Alligator Bioscience: ATOR-1017 Induces Long-Lasting Immunity – New Preclinical Data to be presented at SITC 34th Annual Meeting R
- 24 Oct 2019 Alligator Bioscience AB Interim report January-September 2019 R
- 20 Aug 2019 Alligator Bioscience signs antibody agreement for Greater China with Biotheus Inc. R
- 31 Jul 2019 Alligator Bioscience regains global rights from Janssen to CD40 agonistic antibody, ADC-1013 (JNJ-64457107) R
- 11 Jul 2019 Alligator Bioscience AB (publ) Interim report January-June 2019 R
- 18 Jun 2019 Alligator Bioscience submits clinical trial application for ATOR-1017 R
- 18 Jun 2019 Frontier – A Magazine about Alligator Bioscience and Immuno-oncology
- 16 May 2019 Alligator Bioscience to present the ATOR-1015 Phase I study outline at ASCO R
- 15 May 2019 Alligator Bioscience: ADC-1013 clinical Phase I data to be presented at ASCO R
- 09 May 2019 Bulletin from the Annual Shareholders’ Meeting in Alligator Bioscience AB (publ) on May 9, 2019 R
- 17 Apr 2019 The Nomination Committee’s proposal for the annual shareholders’ meeting in Alligator Bioscience AB (publ) R
- 17 Apr 2019 Alligator Bioscience AB (publ) Interim report January-March 2019 R
- 11 Apr 2019 Alligator Bioscience: Preclinical data on the tumor-localizing anti-CTLA-4 antibody ATOR-1015 published in the Journal for ImmunoTherapy of Cancer R
- 10 Apr 2019 Notice of annual shareholders’ meeting in Alligator Bioscience AB (publ) R
- 10 Apr 2019 Alligator Bioscience to present new preclinical data on ATOR-1015 at PEGS Boston R
- 02 Apr 2019 Alligator Bioscience: New preclinical data for ATOR-1144 demonstrate potential for activation of both the innate and the adaptive immune system, as well as direct anti-tumor effects R
- 22 Mar 2019 Alligator Bioscience’s Annual Report 2018 published R
- 18 Mar 2019 Alligator Bioscience: New preclinical data demonstrate strong anti-tumor effects for the 4-1BB antibody ATOR-1017 R
- 07 Mar 2019 Alligator Bioscience: First Patient Dosed in Phase I study of ATOR-1015 R
- 14 Feb 2019 Alligator Bioscience AB Year-end Report 2018 R
- 12 Feb 2019 Alligator Bioscience to Host Conference Call to Provide Year-end Report 2018 Business Update
- 29 Jan 2019 Alligator Bioscience publishes clinical phase I data for ADC-1013 in the International Journal of Cancer R
- 07 Jan 2019 Alligator Bioscience launches RUBY™, a novel concept in bispecific antibody formats R
-
- 11 Dec 2018 Frontier - A Magazine about Alligator Bioscience and Immuno-oncology
- 11 Dec 2018 Alligator Bioscience starts clinical phase I study with ATOR-1015 R
- 09 Nov 2018 Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting R
- 07 Nov 2018 Alligator Bioscience to receive million-dollar payments - AbClon partner exercises option R
- 06 Nov 2018 Nomination Committee appointed in respect of AGM 2019 in Alligator Bioscience AB R
- 30 Oct 2018 Alligator Bioscience expands pipeline: Preclinical development initiated for the candidate drug ATOR-1144 R
- 26 Oct 2018 Alligator Bioscience AB Interim Report January-September 2018 R
- 05 Oct 2018 Alligator Bioscience receives government research grant R
- 02 Oct 2018 CEO Per Norlén comments on the Nobel Prize in Physiology or Medicine 2018
- 28 Sep 2018 New preclinical data support good tolerability properties for the 4-1BB antibody ATOR-1017 R
- 30 Aug 2018 Alligator Bioscience presents at the 20th Annual Rodman & Renshaw Global Investment Conference
- 19 Jul 2018 Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody R
- 12 Jul 2018 Alligator Bioscience AB Interim Report January-June 2018 R
- 21 Jun 2018 Alligator Bioscience’s ATOR-1017 strongly activates both T cells and NK cells, important for the effective eradication of tumor cells R
- 29 May 2018 Alligator Bioscience Capital Markets Day today on May, 29
- 16 May 2018 Invitation to Alligator Bioscience Capital Markets Day in Stockholm on May 29, 2018
- 08 May 2018 New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 presented by Alligator Bioscience and Aptevo Therapeutics R
- 03 May 2018 Alligator Bioscience: ATOR-1017 pre-clinical data support a best-in-class 4-1BB antibody profile R
- 26 Apr 2018 Bulletin from the Annual Shareholders’ Meeting in Alligator Bioscience AB (publ) on 26 April 2018 R
- 26 Apr 2018 Alligator Bioscience AB Interim Report January-March 2018 R
- 18 Apr 2018 Save the date: Alligator Bioscience to host Capital Markets Day in Stockholm on 29 May 2018
- 17 Apr 2018 Alligator Bioscience presents ATOR-1015 preclinical data at the AACR Annual Meeting 2018 confirming localized tumor activation R
- 05 Apr 2018 Alligator Bioscience presents at the H.C. Wainwright Annual Global Life Sciences Conference
- 22 Mar 2018 Alligator Bioscience’s Annual Report 2017 published R
- 22 Mar 2018 Notice of annual shareholders’ meeting in Alligator Bioscience AB (publ) R
- 16 Feb 2018 Alligator Bioscience AB Full Year Report 2017 R
- 12 Feb 2018 Alligator Bioscience to Host Conference Call to Provide Full Year Report 2017 Business Update
- 25 Jan 2018 Alligator Bioscience contracts Theradex Oncology as clinical CRO for the upcoming ATOR-1015 phase I study R
- 18 Jan 2018 Alligator Bioscience appoints new VP Business Development R
- 04 Jan 2018 Alligator Bioscience to Present at the 10th Annual Biotech Showcase Conference
- 03 Jan 2018 Alligator Bioscience to receive USD 6 million milestone payment from Janssen coupled to the decision to initiate combination trial with ADC-1013 R
-
- 04 Dec 2017 Alligator Bioscience expands management team R
- 21 Nov 2017 Alligator Bioscience AB presents at Redeye Life Science Seminar 24 November 2017
- 13 Nov 2017 Nomination Committee appointed in respect of AGM 2018 in Alligator Bioscience AB R
- 07 Nov 2017 Results from Alligator Bioscience’s clinical phase I study support further clinical development of ADC-1013 R
- 25 Oct 2017 Alligator Bioscience AB Interim Report January-September 2017 R
- 24 Oct 2017 Alligator Bioscience Aptevo Therapeutics: Tumor antigen 5T4 associated with many forms of solid tumors identified as the second target for ALG.APV-527 R
- 21 Sep 2017 Alligator Bioscience to present ADC-1013 intratumoral clinical phase I study results at SITC in November 2017 R
- 13 Sep 2017 Alligator Bioscience signs immunotherapy research collaboration agreement for 4-1BB R
- 23 Aug 2017 Alligator Bioscience AB (Nasdaq Stockholm; ATORX) Interim report January – June 2017 R
- 17 Aug 2017 Aptevo Therapeutics and Alligator Bioscience commence IND-enabling development activities for new bispecific immunotherapy candidate ALG.APV-527 R
- 07 Aug 2017 Alligator expands immuno-oncology collaboration with Stanford University
- 21 Jul 2017 Aptevo Therapeutics and Alligator Bioscience announce plans to co-develop novel bispecific antibody for tumor-directed immunotherapy R
- 12 Jun 2017 Alligator advances 4-1BB immuno-oncology antibody ATOR-1017 to pre-clinical development R
- 04 May 2017 Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ADC-1013 and ATOR-1015 R
- 02 May 2017 Bulletin from the annual shareholders’ meeting in Alligator Bioscience AB (publ) on May 2, 2017 R
- 02 May 2017 Interim Report January-March 2017
- 02 May 2017 Alligator Bioscience AB Interim report January-March 2017 R
- 28 Apr 2017 Alligator Bioscience to present new pre-clinical data for ADC-1013 and ATOR-1015 at PEGS conference in Boston, May 4
- 31 Mar 2017 Change in number of shares and votes in Alligator Bioscience AB (publ) R
- 23 Mar 2017 Alligator announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013 R
- 22 Mar 2017 Alligator Bioscience Annual Report for 2016 published R
- 22 Mar 2017 Notice of annual shareholders’ meeting in Alligator Bioscience AB (publ) R
- 17 Feb 2017 Full Year Report 2016
- 17 Feb 2017 Alligator Bioscience AB Full Year 2016 Report R
- 15 Feb 2017 Conference call for investors, analysts and the media on Friday, February 17 in connection with the company's Full Year Report
- 31 Jan 2017 Change in number of shares and votes in Alligator Bioscience AB (publ) R
-
- 30 Dec 2016 Change in number of shares and votes in Alligator Bioscience AB (publ)
- 23 Dec 2016 Exercise of over-allotment option and notice of stabilisation in Alligator Bioscience
- 16 Dec 2016 Notice of stabilisation measures
- 30 Nov 2016 Change in number of shares and votes in Alligator Bioscience AB
- 23 Nov 2016 Trading of Alligator Bioscience AB on Nasdaq Stockholm commences today R
- 14 Nov 2016 Interim Report January-September 2016
- 14 Nov 2016 Alligator Bioscience AB publishes prospectus for Initial Public Offering on Nasdaq Stockholm
- 02 Nov 2016 Nomination committee appointed in respect of AGM 2017 in Alligator Bioscience AB (Publ)
- 02 Nov 2016 Alligator Bioscience AB intends to list its shares on Nasdaq Stockholm
- 12 Oct 2016 Alligator Bioscience informs that dosing has started in a second clinical phase I study with the CD40 Agonistic Immuno-Oncology Antibody ADC-1013
- 08 Jul 2016 Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015
- 20 May 2016 Alligator receives the SwedenBIO Award!
- 22 Apr 2016 First milestone payment for ADC-1013
- 30 Mar 2016 Documentation of proposals for the annual shareholder's meeting
- 23 Mar 2016 Notice of annual shareholders’ meeting in Alligator Bioscience AB
- 22 Mar 2016 Annual Report 2016
- 04 Mar 2016 Communication of proposals for the extraordinary shareholder’s meeting on 14 March, 2016
- 15 Feb 2016 Notice of extraordinary shareholders’ meeting in Alligator Bioscience AB
-
- 12 Aug 2015 Alligator Bioscience Announces Collaboration with Johnson & Johnson Innovation for the CD40 Agonistic Immuno-Oncology Antibody ADC-1013
- 27 Apr 2015 First Patient Dosed by Alligator Bioscience in a Clinical Phase 1 Multicenter Trial
- 07 Apr 2015 Alligator Bioscience Starts a Clinical Phase 1 Multicenter Trial